Moein Eskandari, Fereshteh Asgharzadeh, Mohammad Mostafa Askarnia-Faal, Hamideh Naimi, Amir Avan, Mitra Ahadi, Hassan Vossoughinia, Masoumeh Gharib, Atena Soleimani, Niloufar Naghibzadeh, Gordon Ferns, Mikhail Ryzhikov, Majid Khazaei, Seyed Mahdi Hassanian
Mebendazole (MBZ) is an efficacious anthelmintic with known anti-inflammatory and fibrinolytic properties. In this study, we aimed to explore the protective effects of this FDA-approved drug against DSS-induced colitis in a murine model either alone or in combination with Sulfasalazine (SSZ), a standard therapy for ulcerative colitis. We found that MBZ significantly improved colitis disease activity index as assessed by changes in body weight, degree of stool consistency, rectal bleeding, and prolapse. We also found that MBZ ameliorated the colon histopathological score by attenuating crypt loss, mucosal damage, and inflammation score in colitis tissues...
June 17, 2022: Scientific Reports